8-K: Current report filing
Published on August 15, 2007
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date
of
Report: August 14, 2007
(Date
of earliest event reported)
NOVELOS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
333-119366
|
04-3321804
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
Number)
|
One
Gateway Center, Suite 504
Newton,
MA 02458
(Address
of principal executive offices)
(617)
244-1616
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
On
August
14, 2007 the Board of Directors of Novelos Therapeutics, Inc. (the “Company”)
elected James S. Manuso, Ph.D. as a director of the Company, to hold office
until the next annual meeting of stockholders and thereafter until his successor
is duly elected. Upon his election, Dr. Manuso received an option to purchase
100,000 shares of the Company’s common stock at an exercise price of $0.56 per
share, vesting quarterly over two years. Dr. Manuso will also receive quarterly
director fees and compensation for meeting attendance consistent with the
Company’s practice for other independent directors.
The
appointment of Dr. Manuso fills the vacancy created by the resignation of Mark
Balazovsky in November 2006.
Item
9.01 Financial
Statements and Exhibits
| (d) |
Exhibits
|
|
10.1
|
Press
Release dated August 15, 2007
|
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: August 15, 2007 | NOVELOS THERAPEUTICS, INC. | |
| |
|
|
| By: | /s/ Harry S. Palmin | |
|
Name: Harry S. Palmin |
||
| Title: President and Chief Executive Officer | ||
3
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
10.1
|
Press
Release dated August 15, 2007
|
|
4